Malignant neoplasms of gynecological system (DC 7627)

Body system: Gynecological ConditionsRegulation: 38 CFR § 4.116DBQ: DBQ GYN Gynecological

DC 7627 covers all malignant neoplasms of the gynecologic system — cancers of the vulva, vagina, cervix, uterus (endometrial and sarcoma), fallopian tubes, ovaries (epithelial, germ-cell, sex-cord-stromal), gestational trophoblastic neoplasia (choriocarcinoma, invasive mole), and primary peritoneal cancer. The VA assigns a flat 100% rating during active disease and active treatment (surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, targeted therapy). The 100% continues for six months after all treatment ends, then a mandatory VA examination determines what residuals remain. After that exam, the cancer DC drops away and chronic residuals are rated separately under their own diagnostic codes — scars (DCs 7800-7805), lymphedema (DC 7121), bowel or bladder dysfunction (DCs 7301, 7332, 7512, 7542), organ-loss (DCs 7617, 7618, 7619), psychiatric (DCs 9411-9434), and so on, combined under 38 CFR § 4.25. Any reduction in the 100% rating is protected by the due-process requirements of 38 CFR § 3.105(e). Recurrence or metastasis restores 100% from the date of recurrence.

Rating levels

  • 100% — You qualify for 100% as long as you have an active gynecologic malignancy or are receiving treatment for one. This includes the period of surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, or any other therapeutic procedure. The 100% rating continues without interruption during the entire active-treatment phase. See the CFR Note below for what happens after treatment ends.
  • -1% — The 100% rating continues for six months after all cancer treatment ends. At the six-month mark, VA must schedule a mandatory examination to decide what residuals remain. The new rating is based on those residuals, NOT on the cancer itself. Examples of residuals: surgical scars (rated under DCs 7800-7805), lymphedema from lymph-node dissection (DC 7121), genitourinary symptoms (voiding dysfunction, UTI under DC 7542 / DC 7512), digestive complications from pelvic radiation (DC 7301 adhesions, DC 7332 fecal incontinence), early surgical menopause (no separate rating, but informs DC 7619 if both ovaries removed), psychiatric residuals (DC 9434 or 9411), and chronic pelvic pain. Anti-pyramiding rules of 38 CFR § 4.14 still apply across residuals. If VA proposes to reduce the rating, the protection of 38 CFR § 3.105(e) applies — VA must notify you 60 days before reduction with reasons and your right to a hearing. If the cancer recurs or metastasizes within the rating period, the 100% rating resumes from the date of recurrence and the six-month clock resets after treatment ends again.

Disclaimer: This tool is for informational purposes only and is not legal or medical advice. Always consult with your VSO representative or a qualified veterans benefits attorney for guidance on your specific claim.